TABLE 2.

Variables associated with S. aureus-related mortality in 294 patients with MSSA-B (cohort study)

Characteristic	Univariate analysis		Multivariate analysisa		Multivariate analysisb
	OR (95% CI)	P value	Adjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Old age (≥65 yr)	1.4 (0.8-2.5)	0.29
Male gender	1.0 (0.6-1.8)	0.98
Community-acquired infection	1.2 (0.7-2.2)	0.52
McCabe classification (ultimately fatal or rapidly fatal)	7.3 (2.8-19.0)	<0.001	2.7 (0.9-7.7)	0.06	2.7 (0.9-7.7)	0.06
Underlying diseases
Solid tumor	6.8 (3.6-13.1)	<0.001	4.7 (2.2-9.9)	<0.001	4.8 (2.2-10.3)	<0.001
Hematologic malignancy	0.4 (0.2-1.0)	0.06
Liver cirrhosis	4.5 (2.4-8.6)	<0.001	3.4 (1.6-7.3)	0.002	3.4 (1.6-7.4)	0.002
End stage renal disease	0.4 (0.1-1.2)	0.09
Cardiovascular disease	0.8 (0.3-2.5)	0.75
Primary sites of infection
Unknown	3.0 (1.7-5.4)	0.001
Catheter-related infection	0.1 (0.0-0.4)	0.002
Pneumonia	2.6 (1.1-6.0)	0.03	2.7 (0.9-7.3)	0.046	2.7 (0.9-7.3)	0.06
Soft tissue infection	0.6 (0.2-1.5)	0.30
Surgical wound infection	0.8 (0.2-3.9)	0.81
Eradicated foci of infection	0.2 (0.1-0.4)	<0.001	0.3 (0.1-0.7)	0.006	0.3 (0.1-0.7)	0.006
Infection acquired in intensive care unit	1.6 (0.6-4.4)	0.34
Inappropriate empirical treatment	1.0 (0.4-2.3)	0.98
Vancomycin treatment	2.8 (1.2-6.4)	0.02	3.4 (1.2-9.3)	0.02	3.3 (1.2-9.5)	0.02

^aAdjusted for the variables associated with S. aureus-related mortality.

^bAdjusted for the variables associated with S. aureus-related mortality and the propensity score of each patient's likelihood of being treated with vancomycin.